While the mechanism of lurbinectedin is still being explored in the tumor and tumor microenvironment, preclinical models indicate that lurbinectedin reduces tumor-associated macrophages (TAMs) and reduces the production of certain inflammation and growth factors, including CCL2 and VEGF [11]. The gene discussed is CCL2; the disease is neoplasm.